Solving the Complexities of T Cell Engager Development
T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells and mediating their cytotoxic effects on tumor cells. However, their complex structure and mechanism of action demand a rigorous understanding of pharmacology, safety, and translational biology.
In this webinar, WuXi AppTec scientists discuss pharmacological approaches for TCEs, including predictive biomarker detection and the use of diverse humanized preclinical models and knock-in systems that recapitulate the immune-tumor microenvironment. Our specialists also address the bioanalytical complexities inherent to TCE therapeutics, including critical considerations in pharmacokinetic profiling and immunogenicity assessment.
Related Content
Varicella-zoster virus (VZV) is a highly contagious alpha-herpesvirus that infects more than 90% of people worldwide. The primary infection with...
VIEW RESOURCEInflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...
VIEW RESOURCE
